Skip to contentS
Syndax Pharmaceuticals Inc
S
SNDXSyndax Pharmaceuticals Inc Q4 2018 · 10-K
Revenue$380.00K$380.00K−68.1% vs Q4 2017 Net Income-$18.84M-$18.84MN/M vs Q4 2017 EPS Diluted$0.70$0.70N/M vs Q4 2017 Operating Income-$19,333,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Syndax Pharmaceuticals Inc · CIK 1395937 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$15,057,000N/M Margins · derivedOperating margin-5087.6%−3454.0 pt vs Q4 2017
Net margin-4957.1%−3355.8 pt vs Q4 2017
ended Dec 31, 2018 · filed Mar 7, 2019 · 66 d after period end